Oncotype DX
Breast cancer patients deciding on chemotherapy
Prices verified Aug 13, 2026 on Oncotype DX's own site
Test Performance
Sensitivity
N/A
Specificity
N/A
Detection Method
Gene expression
Turnaround
10-14 days
Key Features
Predicts chemotherapy benefit • Recurrence risk score • Tumor tissue analysis • Guides treatment decisions
Who It's For
Suited to: Breast cancer patients deciding on chemotherapy
Not suited to: Screening for new cancers
This test is ordered by an oncologist after a cancer diagnosis. It is not a screening test for people without cancer. See the screening tests.
Important Notes
Not a screening test - analyzes existing tumor tissue via a 21-gene expression assay to guide chemotherapy decisions. Standard of care for ER+ breast cancer. 91% of patients pay under $100 and 86% pay $0. Surpassed 2 million patients worldwide (February 2026). Now part of Abbott following its acquisition of Exact Sciences, closed 23 March 2026.
Learn more about Oncotype DX
Discuss with your physician before ordering.
Visit Oncotype DXCompare All